Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 426 entries
Sorted by: Best Match Show Resources per page
Theoretical study on endocrine disrupting effects of polychlorinated dibenzo-p-dioxins using molecular docking simulation.

Journal of applied toxicology : JAT

Akinola LK, Uzairu A, Shallangwa GA, Abechi SE.
PMID: 32656810
J Appl Toxicol. 2021 Feb;41(2):233-246. doi: 10.1002/jat.4039. Epub 2020 Jul 12.

Polychlorinated dibenzo-p-dioxins (PCDDs) are hypothesized to exert their toxic effects in wildlife and humans via endocrine disruption. However, very scanty information is available on the underlying molecular interactions that trigger this disruption. In this study, molecular docking simulation was...

Cite
Akinola LK, Uzairu A, Shallangwa GA, et al. Theoretical study on endocrine disrupting effects of polychlorinated dibenzo-p-dioxins using molecular docking simulation. J Appl Toxicol. 2020;41(2):233-246doi: 10.1002/jat.4039.
Akinola, L. K., Uzairu, A., Shallangwa, G. A., & Abechi, S. E. (2021). Theoretical study on endocrine disrupting effects of polychlorinated dibenzo-p-dioxins using molecular docking simulation. Journal of applied toxicology : JAT, 41(2), 233-246. https://doi.org/10.1002/jat.4039
Akinola, Lukman K, et al. "Theoretical study on endocrine disrupting effects of polychlorinated dibenzo-p-dioxins using molecular docking simulation." Journal of applied toxicology : JAT vol. 41,2 (2021): 233-246. doi: https://doi.org/10.1002/jat.4039
Akinola LK, Uzairu A, Shallangwa GA, Abechi SE. Theoretical study on endocrine disrupting effects of polychlorinated dibenzo-p-dioxins using molecular docking simulation. J Appl Toxicol. 2021 Feb;41(2):233-246. doi: 10.1002/jat.4039. Epub 2020 Jul 12. PMID: 32656810.
Copy Download .nbib Format: NLM
Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT).

Diabetes care

Agrawal L, Azad N, Bahn GD, Reaven PD, Hayward RA, Reda DJ, Emanuele NV.
PMID: 31548245
Diabetes Care. 2019 Nov;42(11):e181-e182. doi: 10.2337/dc19-0891. Epub 2019 Sep 23.

No abstract available.

Cite
Agrawal L, Azad N, Bahn GD, et al. Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2019;42(11):e181-e182doi: 10.2337/dc19-0891.
Agrawal, L., Azad, N., Bahn, G. D., Reaven, P. D., Hayward, R. A., Reda, D. J., Emanuele, N. V. (2019). Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT). Diabetes care, 42(11), e181-e182. https://doi.org/10.2337/dc19-0891
Agrawal, Lily, et al. "Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT)." Diabetes care vol. 42,11 (2019): e181-e182. doi: https://doi.org/10.2337/dc19-0891
Agrawal L, Azad N, Bahn GD, Reaven PD, Hayward RA, Reda DJ, Emanuele NV. Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2019 Nov;42(11):e181-e182. doi: 10.2337/dc19-0891. Epub 2019 Sep 23. PMID: 31548245; PMCID: PMC6804611.
Copy Download .nbib Format: NLM
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.

Clinical pharmacology and therapeutics

Febbo PG, Martin AM, Scher HI, Barrett JC, Beaver JA, Beresford PJ, Blumenthal GM, Bramlett K, Compton C, Dittamore R, Eberhard DA, Edelstein D, Godsey J, Gruen A, Hanlon SE, Hicks J, Hovelson D, Hullings M, Johann D, Johnson J, Kolatkar A, Kuhn P, Levine R, Martini JF, Miller DP, Moore C, Moy B, Pathak A, Philip R, Reese D, Royalty W, Ryder M, Sakul H, Salvatore LM, Schade A, Silvestro A, Simmons JK, Simons J, Singh Bhan S, Smalley MD, Somiari SB, Talasaz A, Tewari M, Tseng HR, Vinson J, Wells W, Welsh A, Grossman RL, Lee JSH, Leiman LC.
PMID: 32017048
Clin Pharmacol Ther. 2020 Apr;107(4):730-734. doi: 10.1002/cpt.1747. Epub 2020 Feb 04.

No abstract available.

Cite
Febbo PG, Martin AM, Scher HI, et al. Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases. Clin Pharmacol Ther. 2020;107(4):730-734doi: 10.1002/cpt.1747.
Febbo, P. G., Martin, A. M., Scher, H. I., Barrett, J. C., Beaver, J. A., Beresford, P. J., Blumenthal, G. M., Bramlett, K., Compton, C., Dittamore, R., Eberhard, D. A., Edelstein, D., Godsey, J., Gruen, A., Hanlon, S. E., Hicks, J., Hovelson, D., Hullings, M., Johann, D., Johnson, J., Kolatkar, A., Kuhn, P., Levine, R., Martini, J. F., Miller, D. P., Moore, C., Moy, B., Pathak, A., Philip, R., Reese, D., Royalty, W., Ryder, M., Sakul, H., Salvatore, L. M., Schade, A., Silvestro, A., Simmons, J. K., Simons, J., Singh Bhan, S., Smalley, M. D., Somiari, S. B., Talasaz, A., Tewari, M., Tseng, H. R., Vinson, J., Wells, W., Welsh, A., Grossman, R. L., Lee, J. S. H., & Leiman, L. C. (2020). Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases. Clinical pharmacology and therapeutics, 107(4), 730-734. https://doi.org/10.1002/cpt.1747
Febbo, Phillip G, et al. "Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases." Clinical pharmacology and therapeutics vol. 107,4 (2020): 730-734. doi: https://doi.org/10.1002/cpt.1747
Febbo PG, Martin AM, Scher HI, Barrett JC, Beaver JA, Beresford PJ, Blumenthal GM, Bramlett K, Compton C, Dittamore R, Eberhard DA, Edelstein D, Godsey J, Gruen A, Hanlon SE, Hicks J, Hovelson D, Hullings M, Johann D, Johnson J, Kolatkar A, Kuhn P, Levine R, Martini JF, Miller DP, Moore C, Moy B, Pathak A, Philip R, Reese D, Royalty W, Ryder M, Sakul H, Salvatore LM, Schade A, Silvestro A, Simmons JK, Simons J, Singh Bhan S, Smalley MD, Somiari SB, Talasaz A, Tewari M, Tseng HR, Vinson J, Wells W, Welsh A, Grossman RL, Lee JSH, Leiman LC. Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases. Clin Pharmacol Ther. 2020 Apr;107(4):730-734. doi: 10.1002/cpt.1747. Epub 2020 Feb 04. PMID: 32017048; PMCID: PMC7158216.
Copy Download .nbib Format: NLM
Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis.

JHEP reports : innovation in hepatology

Oo YH, Ackrill S, Cole R, Jenkins L, Anderson P, Jeffery HC, Jones N, Jeffery LE, Lutz P, Wawman RE, Athwal AK, Thompson J, Gray J, Guo K, Barton D, Hirschfield GM, Wong T, Guest P, Adams DH.
PMID: 32039380
JHEP Rep. 2019 Aug 21;1(4):286-296. doi: 10.1016/j.jhepr.2019.08.001. eCollection 2019 Oct.

Autoimmune hepatitis (AIH) is an immune-mediated disease with no curative treatment. Regulatory T cell (Treg) therapy is potentially curative in AIH given the critical role of Tregs in preventing autoimmunity. To work effectively, adoptively transferred Tregs must migrate to...

Cite
Oo YH, Ackrill S, Cole R, et al. Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis. JHEP Rep. 2019;1(4):286-296doi: 10.1016/j.jhepr.2019.08.001.
Oo, Y. H., Ackrill, S., Cole, R., Jenkins, L., Anderson, P., Jeffery, H. C., Jones, N., Jeffery, L. E., Lutz, P., Wawman, R. E., Athwal, A. K., Thompson, J., Gray, J., Guo, K., Barton, D., Hirschfield, G. M., Wong, T., Guest, P., & Adams, D. H. (2019). Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis. JHEP reports : innovation in hepatology, 1(4), 286-296. https://doi.org/10.1016/j.jhepr.2019.08.001
Oo, Ye Htun, et al. "Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis." JHEP reports : innovation in hepatology vol. 1,4 (2019): 286-296. doi: https://doi.org/10.1016/j.jhepr.2019.08.001
Oo YH, Ackrill S, Cole R, Jenkins L, Anderson P, Jeffery HC, Jones N, Jeffery LE, Lutz P, Wawman RE, Athwal AK, Thompson J, Gray J, Guo K, Barton D, Hirschfield GM, Wong T, Guest P, Adams DH. Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis. JHEP Rep. 2019 Aug 21;1(4):286-296. doi: 10.1016/j.jhepr.2019.08.001. eCollection 2019 Oct. PMID: 32039380; PMCID: PMC7001578.
Copy Download .nbib Format: NLM
Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease.

Hepatology communications

Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E.
PMID: 30094406
Hepatol Commun. 2018 Aug 06;2(8):956-967. doi: 10.1002/hep4.1200. eCollection 2018 Aug.

B cells express an antigen-specific B-cell receptor (BCR) and may contribute to liver inflammation by recognizing shared antigens in the gut and liver. Herein, we used high-throughput BCR sequencing of the immunoglobulin heavy chain, specifically the complementarity-determining region 3...

Cite
Chung BK, Henriksen EKK, Jørgensen KK, et al. Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease. Hepatol Commun. 2018;2(8):956-967doi: 10.1002/hep4.1200.
Chung, B. K., Henriksen, E. K. K., Jørgensen, K. K., Karlsen, T. H., Hirschfield, G. M., & Liaskou, E. (2018). Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease. Hepatology communications, 2(8), 956-967. https://doi.org/10.1002/hep4.1200
Chung, Brian K, et al. "Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease." Hepatology communications vol. 2,8 (2018): 956-967. doi: https://doi.org/10.1002/hep4.1200
Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E. Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease. Hepatol Commun. 2018 Aug 06;2(8):956-967. doi: 10.1002/hep4.1200. eCollection 2018 Aug. PMID: 30094406; PMCID: PMC6078219.
Copy Download .nbib Format: NLM
Challenges with Novel Clinical Trial Designs: Master Protocols.

Clinical cancer research : an official journal of the American Association for Cancer Research

Cecchini M, Rubin EH, Blumenthal GM, Ayalew K, Burris HA, Russell-Einhorn M, Dillon H, Lyerly HK, Reaman GH, Boerner S, LoRusso PM.
PMID: 30696689
Clin Cancer Res. 2019 Apr 01;25(7):2049-2057. doi: 10.1158/1078-0432.CCR-18-3544. Epub 2019 Jan 29.

The 2018 Accelerating Anticancer Agent Development (AAADV) Workshop assembled a panel of experts for an in-depth discussion session to present "Challenges with Novel Clinical Trial Designs." This panel offered assessments of the challenges faced by industry, the FDA, investigators,...

Cite
Cecchini M, Rubin EH, Blumenthal GM, et al. Challenges with Novel Clinical Trial Designs: Master Protocols. Clin Cancer Res. 2019;25(7):2049-2057doi: 10.1158/1078-0432.CCR-18-3544.
Cecchini, M., Rubin, E. H., Blumenthal, G. M., Ayalew, K., Burris, H. A., Russell-Einhorn, M., Dillon, H., Lyerly, H. K., Reaman, G. H., Boerner, S., & LoRusso, P. M. (2019). Challenges with Novel Clinical Trial Designs: Master Protocols. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(7), 2049-2057. https://doi.org/10.1158/1078-0432.CCR-18-3544
Cecchini, Michael, et al. "Challenges with Novel Clinical Trial Designs: Master Protocols." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 25,7 (2019): 2049-2057. doi: https://doi.org/10.1158/1078-0432.CCR-18-3544
Cecchini M, Rubin EH, Blumenthal GM, Ayalew K, Burris HA, Russell-Einhorn M, Dillon H, Lyerly HK, Reaman GH, Boerner S, LoRusso PM. Challenges with Novel Clinical Trial Designs: Master Protocols. Clin Cancer Res. 2019 Apr 01;25(7):2049-2057. doi: 10.1158/1078-0432.CCR-18-3544. Epub 2019 Jan 29. PMID: 30696689.
Copy Download .nbib Format: NLM
Recovery After Genocide: Understanding the Dimensions of Recovery Capital Among Incarcerated Genocide Perpetrators in Rwanda.

Frontiers in psychology

Barnes-Ceeney K, Gideon L, Leitch L, Yasuhara K.
PMID: 31040801
Front Psychol. 2019 Apr 16;10:637. doi: 10.3389/fpsyg.2019.00637. eCollection 2019.

Utilizing survey data from 302 men and women incarcerated in the Rwandan correctional system for the crime of genocide, and structured interviews with 75 prisoners, this mixed methods study draws on the concept of recovery capital to understand how...

Cite
Barnes-Ceeney K, Gideon L, Leitch L, et al. Recovery After Genocide: Understanding the Dimensions of Recovery Capital Among Incarcerated Genocide Perpetrators in Rwanda. Front Psychol. 2019;10:637doi: 10.3389/fpsyg.2019.00637.
Barnes-Ceeney, K., Gideon, L., Leitch, L., & Yasuhara, K. (2019). Recovery After Genocide: Understanding the Dimensions of Recovery Capital Among Incarcerated Genocide Perpetrators in Rwanda. Frontiers in psychology, 10637. https://doi.org/10.3389/fpsyg.2019.00637
Barnes-Ceeney, Kevin, et al. "Recovery After Genocide: Understanding the Dimensions of Recovery Capital Among Incarcerated Genocide Perpetrators in Rwanda." Frontiers in psychology vol. 10 (2019): 637. doi: https://doi.org/10.3389/fpsyg.2019.00637
Barnes-Ceeney K, Gideon L, Leitch L, Yasuhara K. Recovery After Genocide: Understanding the Dimensions of Recovery Capital Among Incarcerated Genocide Perpetrators in Rwanda. Front Psychol. 2019 Apr 16;10:637. doi: 10.3389/fpsyg.2019.00637. eCollection 2019. PMID: 31040801; PMCID: PMC6476899.
Copy Download .nbib Format: NLM
Adverse Health Outcomes Associated with Postdiagnosis Smoking in Prostate Cancer Patients: A Literature Review.

Journal of medical imaging and radiation sciences

Ganesh V, Zaki P, Chan S, Turner A, Bristow B, Di Prospero L, Gibson L, DeAngelis C, Chow E.
PMID: 31047202
J Med Imaging Radiat Sci. 2017 Mar;48(1):103-110. doi: 10.1016/j.jmir.2016.11.006. Epub 2017 Feb 16.

This literature review presents what is currently known about the association between postdiagnosis smoking and adverse health outcomes in prostate cancer. A literature search was conducted using Ovid Embase and Ovid MEDLINE. Information from 36 studies was summarized. There...

Cite
Ganesh V, Zaki P, Chan S, et al. Adverse Health Outcomes Associated with Postdiagnosis Smoking in Prostate Cancer Patients: A Literature Review. J Med Imaging Radiat Sci. 2017;48(1):103-110doi: 10.1016/j.jmir.2016.11.006.
Ganesh, V., Zaki, P., Chan, S., Turner, A., Bristow, B., Di Prospero, L., Gibson, L., DeAngelis, C., & Chow, E. (2017). Adverse Health Outcomes Associated with Postdiagnosis Smoking in Prostate Cancer Patients: A Literature Review. Journal of medical imaging and radiation sciences, 48(1), 103-110. https://doi.org/10.1016/j.jmir.2016.11.006
Ganesh, Vithusha, et al. "Adverse Health Outcomes Associated with Postdiagnosis Smoking in Prostate Cancer Patients: A Literature Review." Journal of medical imaging and radiation sciences vol. 48,1 (2017): 103-110. doi: https://doi.org/10.1016/j.jmir.2016.11.006
Ganesh V, Zaki P, Chan S, Turner A, Bristow B, Di Prospero L, Gibson L, DeAngelis C, Chow E. Adverse Health Outcomes Associated with Postdiagnosis Smoking in Prostate Cancer Patients: A Literature Review. J Med Imaging Radiat Sci. 2017 Mar;48(1):103-110. doi: 10.1016/j.jmir.2016.11.006. Epub 2017 Feb 16. PMID: 31047202.
Copy Download .nbib Format: NLM
Categorized Affective Pictures Database (CAP-D).

Journal of cognition

Moyal N, Henik A, Anholt GE.
PMID: 31517214
J Cogn. 2018 Sep 26;1(1):41. doi: 10.5334/joc.47.

Emotional picture databases are commonly used in emotion research. The databases were first based on ratings of emotional dimensions, and the interest in studying discrete emotions led to the categorization of subsets from these databases to emotional categories. However,...

Cite
Moyal N, Henik A, Anholt GE. Categorized Affective Pictures Database (CAP-D). J Cogn. 2018;1(1):41doi: 10.5334/joc.47.
Moyal, N., Henik, A., & Anholt, G. E. (2018). Categorized Affective Pictures Database (CAP-D). Journal of cognition, 1(1), 41. https://doi.org/10.5334/joc.47
Moyal, Natali, et al. "Categorized Affective Pictures Database (CAP-D)." Journal of cognition vol. 1,1 (2018): 41. doi: https://doi.org/10.5334/joc.47
Moyal N, Henik A, Anholt GE. Categorized Affective Pictures Database (CAP-D). J Cogn. 2018 Sep 26;1(1):41. doi: 10.5334/joc.47. PMID: 31517214; PMCID: PMC6634429.
Copy Download .nbib Format: NLM
Designed to Fail? Revisiting Uganda's Maternal Health Policies to Understand Policy Design Issues Underpinning Missed Targets for Reduction of Maternal Mortality Ratio (MMR): 2000-2015.

International journal of health policy and management

Mukuru M, Gorry J, Kiwanuka SN, Gibson L, Musoke D, Ssengooba F.
PMID: 34664495
Int J Health Policy Manag. 2021 Sep 07; doi: 10.34172/ijhpm.2021.127. Epub 2021 Sep 07.

BACKGROUND: Despite Uganda and other sub-Saharan African countries missing their maternal mortality ratio (MMR) targets for Millennium Development Goal (MDG) 5, limited attention has been paid to policy design in the literature examining the persistence of preventable maternal mortality....

Cite
Mukuru M, Gorry J, Kiwanuka SN, et al. Designed to Fail? Revisiting Uganda's Maternal Health Policies to Understand Policy Design Issues Underpinning Missed Targets for Reduction of Maternal Mortality Ratio (MMR): 2000-2015. Int J Health Policy Manag. 2021;doi: 10.34172/ijhpm.2021.127.
Mukuru, M., Gorry, J., Kiwanuka, S. N., Gibson, L., Musoke, D., & Ssengooba, F. (2021). Designed to Fail? Revisiting Uganda's Maternal Health Policies to Understand Policy Design Issues Underpinning Missed Targets for Reduction of Maternal Mortality Ratio (MMR): 2000-2015. International journal of health policy and management, . https://doi.org/10.34172/ijhpm.2021.127
Mukuru, Moses, et al. "Designed to Fail? Revisiting Uganda's Maternal Health Policies to Understand Policy Design Issues Underpinning Missed Targets for Reduction of Maternal Mortality Ratio (MMR): 2000-2015." International journal of health policy and management vol. (2021). doi: https://doi.org/10.34172/ijhpm.2021.127
Mukuru M, Gorry J, Kiwanuka SN, Gibson L, Musoke D, Ssengooba F. Designed to Fail? Revisiting Uganda's Maternal Health Policies to Understand Policy Design Issues Underpinning Missed Targets for Reduction of Maternal Mortality Ratio (MMR): 2000-2015. Int J Health Policy Manag. 2021 Sep 07; doi: 10.34172/ijhpm.2021.127. Epub 2021 Sep 07. PMID: 34664495.
Copy Download .nbib Format: NLM
Enhancing Performance and Sustainability of Community Health Worker Programs in Uganda: Lessons and Experiences From Stakeholders.

Global health, science and practice

Musoke D, Atusingwize E, Ndejjo R, Ssemugabo C, Siebert P, Gibson L.
PMID: 34933981
Glob Health Sci Pract. 2021 Dec 21;9(4):855-868. doi: 10.9745/GHSP-D-21-00260. Print 2021 Dec 31.

BACKGROUND: Community health worker (CHW) programs in Uganda have contributed to improved health outcomes in recent years. However, opportunities for engaging the various stakeholders supporting CHW programs have been limited. This article presents workshop findings where several stakeholders shared...

Cite
Musoke D, Atusingwize E, Ndejjo R, et al. Enhancing Performance and Sustainability of Community Health Worker Programs in Uganda: Lessons and Experiences From Stakeholders. Glob Health Sci Pract. 2021;9(4):855-868doi: 10.9745/GHSP-D-21-00260.
Musoke, D., Atusingwize, E., Ndejjo, R., Ssemugabo, C., Siebert, P., & Gibson, L. (2021). Enhancing Performance and Sustainability of Community Health Worker Programs in Uganda: Lessons and Experiences From Stakeholders. Global health, science and practice, 9(4), 855-868. https://doi.org/10.9745/GHSP-D-21-00260
Musoke, David, et al. "Enhancing Performance and Sustainability of Community Health Worker Programs in Uganda: Lessons and Experiences From Stakeholders." Global health, science and practice vol. 9,4 (2021): 855-868. doi: https://doi.org/10.9745/GHSP-D-21-00260
Musoke D, Atusingwize E, Ndejjo R, Ssemugabo C, Siebert P, Gibson L. Enhancing Performance and Sustainability of Community Health Worker Programs in Uganda: Lessons and Experiences From Stakeholders. Glob Health Sci Pract. 2021 Dec 21;9(4):855-868. doi: 10.9745/GHSP-D-21-00260. Print 2021 Dec 31. PMID: 34933981; PMCID: PMC8691894.
Copy Download .nbib Format: NLM
Configurational Entropy Relaxation of Silica Glass-Molecular Dynamics Simulations.

Entropy (Basel, Switzerland)

Gedeon O.
PMID: 34356426
Entropy (Basel). 2021 Jul 13;23(7). doi: 10.3390/e23070885.

Vitreous silica was modelled using molecular dynamics (MD). The glass structure was transferred into an undirected graph and decomposed into disjoint structural units that were ideally mixed to calculate the configurational entropy. The Debye relaxation model was suggested to...

Cite
Gedeon O. Configurational Entropy Relaxation of Silica Glass-Molecular Dynamics Simulations. Entropy (Basel). 2021;23(7)doi: 10.3390/e23070885.
Gedeon, O. (2021). Configurational Entropy Relaxation of Silica Glass-Molecular Dynamics Simulations. Entropy (Basel, Switzerland), 23(7), . https://doi.org/10.3390/e23070885
Gedeon, Ondrej. "Configurational Entropy Relaxation of Silica Glass-Molecular Dynamics Simulations." Entropy (Basel, Switzerland) vol. 23,7 (2021). doi: https://doi.org/10.3390/e23070885
Gedeon O. Configurational Entropy Relaxation of Silica Glass-Molecular Dynamics Simulations. Entropy (Basel). 2021 Jul 13;23(7). doi: 10.3390/e23070885. PMID: 34356426; PMCID: PMC8305701.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 426 entries